Relay Therapeutics, a Cambridge, Massachusetts-based newly formed drug discovery company, raised $57m in Series A financing.
The round was led by founding investors Third Rock Ventures, with participation from an affiliate of D. E. Shaw Research, LLC.
Led by Alexis Borisy, Executive Chairman, interim CEO, and Partner at Third Rock Ventures, and Mark Murcko, Ph.D., Chief Scientific Officer, Relay Therapeutics is building a dedicated drug discovery platform centered on protein motion to design and develop new medicines, building on recent scientific and technological advances in structural biology, biophysics, computation, chemistry and biology.
The company’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying these technologies as an integrated team focused on disease-causing targets, Relay initially aims to develop medicines for oncology patients in need.
Founders of the company include
– Matthew Jacobson, Ph.D., Professor and Pharmaceutical Chemistry Department Chair, University of California, San Francisco (UCSF)
– Dorothee Kern, Ph.D., Professor, Brandeis University; Investigator, Howard Hughes Medical Institute
– Mark Murcko, Ph.D., Chief Scientific Officer and Co-Founder, Relay Therapeutics; Senior Lecturer, Massachusetts Institute of Technology (MIT), and
– D. E. Shaw Research (David E. Shaw, Ph.D., Chief Scientist)
FinSMEs
15/09/2016